🔥BREAKING NEWS🔥
@TOPAS is now @OpenTOPAS!
The TOPAS team has moved to a full @open-source approach with major upgrades.
Spread the word and check out v4.0 for @Geant4 v11.1.3 at:
https://t.co/S2OYeUSaJ4
Our future developments, a new forum, and documentation will be there
In patients treated with ¹⁷⁷Lu-DOTATATE for GEP-NETs, tumor and healthy organ dosimetry can predict survival and toxicities, influencing clinical management. https://t.co/pmGwFLGz4J
#NuclearMedicine#RPTherapy#NeuroendocrineTumors
We're hiring!🚨Join our team at @MGHCancerCenter and @harvardmed. We are looking for a postdoctoral fellow who's interested in AI, outcome modeling and radiotherapy. If you're interested, we want to hear from you. Apply by April 30! 📅 Find out more here: https://t.co/lnEez3lQz2
Don’t miss the BEST IN PHYSICS poster, displayed NOW at booth 1 in the exhibit hall. Come see the super cool work by 🌟@chuesaberral from @bertoletlab on novel model of microspheres distribution in liver tumors. #AAPM2023 @MGHCancerCenter @HarvardMedPhys
Randomized study published in Lancet today, showing 62% EFS improvement with Nivo + SABR compared with SABR alone in early stage NSCLC. I-SABR is a promising TX option.
awbs://authors.elsevier.com/c/1hRV5V-4XL3dJ
@IASLC@MDAndersonNews@TheLancet@ACKoongMDPhD@StephenVLiu
Cancer is a terrible disease, and also one that we all know too well.
It is not a new problem, rather one that exists since thousands of years & is studied in unimaginable detail.
Then why do people still die of cancer?
Let's start understanding this by taking a step back.
Interestingly, both studies are somewhat connected, as considering and modeling the complexity of DNA damage and its subsequent repair processes could be a refined way to develop RBE models for particle therapy instead of just looking at clonogenic survival assays.
@TsaUnderwood@kiwiddraig Thank you, Tracy. I agree with you that in-person is better to focus on building connections. But travel expanse is always an issue for early career researchers.
Upright radiotherapy is a field full of scientific opportunities. Internationally, we are still a small group of researchers, but we are a warm & dynamic community. If you are interested in learning more, please consider attending our first in-person 'Research Consortium Meeting'
Happy New Year Everyone!
Today I return to work and I have good news ✍️
I've published my first book chapter
➡️Data-Driven Approaches in Radiotherapy Outcome Modeling https://t.co/MozHh2NSOh
With @CGrassberger and Y. Kim 🚨
@MGHCancerCenter @HarvardMedPhys@harvard_data
With the pending return to long-duration crewed #spaceflights, astronauts will face significant risks from exposure to space radiation such as galactic #cosmicrays. https://t.co/75vWVEm7tP
🎙️Great talk by Liesbeth Boersma about the Dutch model-based approach for proton patient selection:
- great model performance, see predicted vs observed dysph & RP incidence! 📊
- they have a model for seminona!! @sophia_kamran
Looking forward to prospective validation!!